News
RNLX
0.6995
-6.30%
-0.0470
Renalytix AI Announces Fundraising, Executive Changes, and Shareholder Approval
TipRanks · 19h ago
Weekly Report: what happened at RNLX last week (0415-0419)?
Weekly Report · 2d ago
Renalytix files to sell 19.99M ordinary shares for holders
Seeking Alpha · 6d ago
Weekly Report: what happened at RNLX last week (0408-0412)?
Weekly Report · 04/15 11:21
Renalytix AI Announces Convertible Bond Repayments and Share Issuance
TipRanks · 04/10 20:12
Renalytix AI Announces Non-Filed $4 Million Financing Plan
TipRanks · 04/08 11:52
Renalytix Announces Financing with Expected Size of up to $4M at $0.75/Nasdaq ADS
Renalytix plc announces a registered direct offering of ordinary shares at a purchase price equivalent to $0.75 per common stock share. The net proceeds of the Fundraise will be used to support commercial sales of the company's medical technology. The company's shares are listed on the NASDAQ and the LSE.
Benzinga · 04/08 11:28
Weekly Report: what happened at RNLX last week (0401-0405)?
Weekly Report · 04/08 11:26
Renalytix announces $1M registered direct offering, financing with expected size of up to $4M
Healthcare Renalytix announces $1M registered direct offering, financing with expected size of up to $4M. The company has an option to exercise subsequent tranche of ordinary shares at same price till April 17, 2024. The net proceeds will be used to support commercial sales activity.
Seeking Alpha · 04/08 11:21
Renalytix PLC 13G Filing Shows CVI Investments, Inc. Reported A 6.9% Stake In the Co As Of March 28, 2024
Benzinga · 04/04 14:21
CVI INVESTMENTS INC REPORTS 6.9% PASSIVE STAKE IN RENALYTIX PLC AS OF MARCH 28- SEC FILING
Reuters · 04/04 14:17
Weekly Report: what happened at RNLX last week (0325-0329)?
Weekly Report · 04/01 11:24
Weekly Report: what happened at RNLX last week (0318-0322)?
Weekly Report · 03/25 11:27
Weekly Report: what happened at RNLX last week (0311-0315)?
Weekly Report · 03/18 11:25
Renalytix AI’s KidneyIntelX™ Endorsed in KDIGO Guidelines
Renalytix's KidneyIntelX™ product has been included in the final 2024 KDIGO guidelines for Chronic Kidney Disease. The inclusion is a significant endorsement from the medical community. The company's product is now in the market for the treatment of chronic kidney disease.
TipRanks · 03/14 11:32
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. HUTCHMED (China) stock increased by 14.04% in the pre- market session. Kintara Therapeutics (NASdaq:KTRA) and Qilian Intl. Gr (Qilian) were among the losers.
Benzinga · 03/13 13:06
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Asana, Inc. Fell 11% to $16.72 on Tuesday. Asana reported soft FY25 revenue guidance. ClearOne, Inc., rose 168.4% in the mid-day session. Regulus Therapeutics Inc. Shares rose 74.3% after posting strong quarterly results.
Benzinga · 03/12 18:07
12 Health Care Stocks Moving In Tuesday's Intraday Session
Regulus Therapeutics stock increased by 94.9% to $2.69 during Tuesday's regular session. Bright Green (NASDAQ:BGXX) shares increased by 66.42%. SCWorx and Assure Hldgs stock moved upwards by 29.33%. Lexaria Bioscience and NRX Pharmaceuticals were among the losers.
Benzinga · 03/12 17:31
Renalytix, CareMax, TC BioPharm among healthcare movers
Healthcare On the Move: Renalytix, CareMax, TC BioPharm among healthcare movers. S&P 500 Health Care Sector -0.08% to 1701.07. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 03/12 14:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Regulus Therapeutics (NASDAQ:RGLS) stock moved upwards by 84.8% to $2.55 during Tuesday's pre-market session. Assure Hldgs stock increased by 73.02% in the pre- market session. Telomir Pharmaceuticals and Bioventus also moved upwards.
Benzinga · 03/12 13:05
More
Webull provides a variety of real-time RNLX stock news. You can receive the latest news about Renalytix Plc through multiple platforms. This information may help you make smarter investment decisions.
About RNLX
Renalytix plc is a United Kingdom-based company, which is engaged in the development of artificial intelligence-enabled clinical diagnostic solutions for kidney disease. The Company is engaged in a field of bioprognosis for kidney health. The Company has engineered a solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX platform, is designed to scale across kidney disease conditions beyond diabetic kidney disease. It is evaluating a range of indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and COVID-related kidney disease. KidneyIntelX has been granted designation by the United States Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.